BioCryst appoints Dr. Jill Milne to Compensation and Science Committees following Astria merger close

BIOCRYST PHARMACEUTICALS INC

Merger with Astria Therapeutics completed on January 23, 2026; Astria becomes wholly owned subsidiary.
Dr. Jill C. Milne appointed to BioCryst Board of Directors effective as of closing date.
On January 20, 2026, Board appointed Dr. Milne to Compensation and Science Committees.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.